Portfolio Company · Operating Co.

Escient Pharmaceuticals

Healthcare, Life Sciences · Website

backed byNew Enterprise Associates

ExitedHealthcare, Life Sciences

a portfolio company of

New Enterprise Associates

Status on record: Exited

PE Firm Index

Who owns Escient Pharmaceuticals?

Escient Pharmaceuticals is listed as an exited portfolio company of New Enterprise Associates on New Enterprise Associates' own portfolio page.

From the company's website

We apply state-of-the-art medicinal chemistry and biological tools to develop targeted small molecule therapeutics that hold potential to become novel, highly differentiated treatment options for a broad range of diseases.

Source: escientpharma.com, read November 2026

Company Snapshot

Escient Pharmaceuticals is a Healthcare, Life Sciences company. Its owner on record, New Enterprise Associates, is a firm. New Enterprise Associates lists at least 49 companies in the index, 19 of them in Healthcare, Life Sciences.

SectorHealthcare, Life Sciences

Parent PE firmNew Enterprise Associates

Ownership statusExited

WebsiteVisit ↗

About the owner

New Enterprise Associates

Companies in the index: At least 49

Global venture capital firm investing in technology and healthcare.

Read the New Enterprise Associates profile

Questions about Escient Pharmaceuticals

Who owns Escient Pharmaceuticals?

Escient Pharmaceuticals is listed as an exited portfolio company of New Enterprise Associates on New Enterprise Associates' own portfolio page.

What sector is Escient Pharmaceuticals in?

Escient Pharmaceuticals is in Healthcare, Life Sciences. Classified from the owner's portfolio label.

What else does New Enterprise Associates own in Healthcare, Life Sciences?

New Enterprise Associates lists 18 other Healthcare, Life Sciences companies in the index, including Celcuity, Comprehensive Pharmacy Services, Corxel, corxel-b&w and CRISPR Therapeutics.

What is Escient Pharmaceuticals' website?

Escient Pharmaceuticals' website is https://www.escientpharma.com/.

Sources

New Enterprise Associates' page on Escient Pharmaceuticals
New Enterprise Associates
https://www.nea.com/portfolio

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Escient Pharmaceuticals and does not provide investment advice.

Other portfolio companies of New Enterprise Associates

6 of 48 shown

Brale

Technology, Fintech

Celcuity

Healthcare, Life Sciences

Cloudflare

Technology, Enterprise

Comprehensive Pharmacy Services

Healthcare, Digital Health

Corxel

Healthcare, Life Sciences

corxel-b&w

Healthcare, Life Sciences

See the full New Enterprise Associates portfolio.

Other Healthcare, Life Sciences companies held by New Enterprise Associates

Celcuity Comprehensive Pharmacy Services Corxel corxel-b&w CRISPR Therapeutics Curana Health

Other Healthcare, Life Sciences portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

New Enterprise Associates

Status: Exited

Check this company's website

Check this company's website now

Free, in about two minutes: the verified issues a buyer or a customer's browser would meet. Runs on GTM Brain, by DevriX.

Observational measurements of this company's public website only. Not a rating of the company, its performance, its management, or its investment merit. Not investment advice. Request a correction or removal via Submit Update.

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.